Dorien Clarisse

Dr. Dorien Clarisse

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2020 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
KBKarolien De Bosscher
Karolien De Bosscher
SDSofie J. Desmet
Sofie J. Desmet
DCDorien Clarisse
Dorien Clarisse
Eva Estebanez-PerpinaEva Estebanez-Perpina
Eva Estebanez-Perpina
LBLuc Brunsveld
Luc Brunsveld

19 May 2022 in Journal of Chemistry
Verified
Journal Article
Open access
PDF file
KBKato Bredael
Kato Bredael
SGSilke Geurs
Silke Geurs
DCDorien Clarisse
Dorien Clarisse
KBKarolien De Bosscher
Karolien De Bosscher
MDMatthias D'hooghe
Matthias D'hooghe
Lead optimization represents the tedious process of fine-tuning lead compounds from biologically active hits to suitable drug candidates for clinical trials. By chemically modifying a hit structure, an improved compound can be obtained in terms of activity, selectivity, and pharmacokinetic ADME (absorption, distribution, metabolism, and excretion) properties. The carboxylic acid moiety is known to be a crucial functionality in many pharmaceutically active compounds. Despite its common use as a key functionality in drugs, its presence in a lead molecule is often associated with poor pharmacokinetic properties and toxicity. In this literature overview, we discuss how the shortcomings of a carboxylic acid can be circumvented by replacing this functionality with bioisosteres. In this way, the positive aspects of this moiety, such as its activity, for example, by virtue of its capacity to form hydrogen bonds, can be maintained or even improved. To that end, we provide an overview of the most promising carboxylic acid bioisosteres and discuss a selection of synthetic routes towards the main functionalities.

24 February 2011 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
PBPatrick Bultinck
Patrick Bultinck
DCDorien Clarisse
Dorien Clarisse
PAPaul Ayers
Paul Ayers
RCRamon Carbó-Dorca
Ramon Carbó-Dorca
The Fukui matrix is introduced as the derivative of the one-electron reduced density matrix with respect to a change in the number of electrons under constant external potential. The Fukui matrix extends the Fukui function concept: the diagonal of the Fukui matrix is the Fukui function. Diagonalizing the Fukui matrix gives a set of eigenvectors, the Fukui orbitals, and accompanying eigenvalues. At the level of theory used, there is always one dominant eigenvector, with an eigenvalue equal to 1. The remaining eigenvalues are either zero or come in pairs with eigenvalues of the same magnitude but opposite sign. Analysis of the frontier molecular orbital coefficient in the eigenvector with eigenvalue 1 gives information on the quality of the frontier molecular orbital picture. The occurrence of negative Fukui functions can be easily interpreted in terms of the nodal character of the dominant eigenvector versus the characteristics of the remaining eigenvectors and eigenvalues.

29 February 2024 in Trends in Biochemical Sciences
Verified
Journal Article
Open access
DCDorien Clarisse
Dorien Clarisse
LMLaura Van Moortel
Laura Van Moortel
CLChloé Van Leene
Chloé Van Leene
KGKris Gevaert
Kris Gevaert
KBKarolien De Bosscher
Karolien De Bosscher
The glucocorticoid receptor (GR) is a major nuclear receptor (NR) drug target for the treatment of inflammatory disorders and several cancers. Despite the effectiveness of GR ligands, their systemic action triggers a plethora of side effects, limiting long-term use. Here, we discuss new concepts of and insights into GR mechanisms of action to assist in the identification of routes toward enhanced therapeutic benefits. We zoom in on the communication between different GR domains and how this is influenced by different ligands. We detail findings on the interaction between GR and chromatin, and highlight how condensate formation and coregulator confinement can perturb GR transcriptional responses. Last, we discuss the potential of novel ligands and the therapeutic exploitation of crosstalk with other NRs.

1 December 2020 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Open access
DCDorien Clarisse
Dorien Clarisse
FOFritz Offner
Fritz Offner
KBKarolien De Bosscher
Karolien De Bosscher
Glucocorticoids are essential drugs in the treatment protocols of lymphoid malignancies. These steroidal hormones trigger apoptosis of the malignant cells by binding to the glucocorticoid receptor (GR), which is a member of the nuclear receptor superfamily. Long term glucocorticoid treatment is limited by two major problems: the development of glucocorticoid-related side effects, which hampers patient quality of life, and the emergence of glucocorticoid resistance, which is a gradual process that is inevitable in many patients. This emphasizes the need to reevaluate and optimize the widespread use of glucocorticoids in lymphoid malignancies. To achieve this goal, a deep understanding of the mechanisms governing glucocorticoid responsiveness is required, yet, a recent comprehensive overview is currently lacking. In this review, we examine how glucocorticoids mediate apoptosis by detailing GR's genomic and non-genomic action mechanisms in lymphoid malignancies. We continue with a discussion of the glucocorticoid-related problems and how these are intertwined with one another. We further zoom in on glucocorticoid resistance by critically analyzing the plethora of proposed mechanisms and highlighting therapeutic opportunities that emerge from these studies. In conclusion, early detection of glucocorticoid resistance in patients remains an important challenge as this would result in a timelier treatment reorientation and reduced glucocorticoid-instigated side effects.

30 July 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IBIlse M. Beck
Ilse M. Beck
ZDZuzanna J. Drebert
Zuzanna J. Drebert
RHRuben Hoya-Arias
Ruben Hoya-Arias
ABAli A. Bahar
Ali A. Bahar
MDMichael Devos
Michael Devos
KBKarolien De Bosscher
Karolien De Bosscher
Compound A possesses glucocorticoid receptor (GR)-dependent anti-inflammatory properties. Just like classical GR ligands, Compound A can repress NF-κB-mediated gene expression. However, the monomeric Compound A-activated GR is unable to trigger glucocorticoid response element-regulated gene expression. The heat shock response potently activates heat shock factor 1 (HSF1), upregulates Hsp70, a known GR chaperone, and also modulates various aspects of inflammation. We found that the selective GR modulator Compound A and heat shock trigger similar cellular effects in A549 lung epithelial cells. With regard to their anti-inflammatory mechanism, heat shock and Compound A are both able to reduce TNF-stimulated IκBα degradation and NF-κB p65 nuclear translocation. We established an interaction between Compound A-activated GR and Hsp70, but remarkably, although the presence of the Hsp70 chaperone as such appears pivotal for the Compound A-mediated inflammatory gene repression, subsequent novel Hsp70 protein synthesis is uncoupled from an observed CpdA-induced Hsp70 mRNA upregulation and hence obsolete in mediating CpdA’s anti-inflammatory effect. The lack of a Compound A-induced increase in Hsp70 protein levels in A549 cells is not mediated by a rapid proteasomal degradation of Hsp70 or by a Compound A-induced general block on translation. Similar to heat shock, Compound A can upregulate transcription of Hsp70 genes in various cell lines and BALB/c mice. Interestingly, whereas Compound A-dependent Hsp70 promoter activation is GR-dependent but HSF1-independent, heat shock-induced Hsp70 expression alternatively occurs in a GR-independent and HSF1-dependent manner in A549 lung epithelial cells.